; related to Figure 1. Sema-PlxnD1 signaling limits the abundance of arterial angiogenic cells and axial vasculature ECs and is cell-autonomously required in the endothelium. 
hu4624 reporter in WT and obd with or without 10 ng of mib morpholino (mib MO). n = 10 for WT, n = 12 for obd, n = 11 for WT (mib MO) and n = 9 for obd (mib MO). (B) Validation of the sflt1-splice MO, DNA electrophoresis gel. Lane 1, 100 bp DNA ladder. Lanes 2-7, RT-PCR products obtained from embryos treated with 25 ng of sflt1-ctrl (lanes 2, 4, 6) or sflt1-splice MOs (lanes 3, 5, 7). The correctly spliced sflt1 RT-PCR product (85 bp) seen in sflt1-ctrl morphants (lane 2) is absent from sflt1-splice morphants (lane 3), which show two products larger (red arrows) than those seen in correctly spliced sflt1. Hence, the sflt1-splice MO appears to block the canonical splice site at the intron 10/11a-exon 11a junction, forcing the use of a cryptic splice site (Morcos, 2007) . mflt1 and bactin2 are unaffected by either sflt1 MO (lanes 4-7). -mediated EC-specific mosaic mFlt1 over-expression can induce ectopic and mispatterned SeA sprouts in WT embryos. 32 hpf trunk vasculature (green) with EC-specific co-expression of mFlt1 and DsRed (red). White arrowheads, ectopic DsRed + SeA sprout over-expressing mFlt1. Blue arrowheads, misshapen EC overexpressing mFlt1 found within a properly positioned SeA. White asterisks, properly positioned SeA sprouts without mFlt1 over-expression. 
Supplemental Experimental Procedures

Zebrafish Lines
The following endothelial cell (EC)-specific transgenic fluorescent reporter lines were used: Tg(fli: EGFP) y1 (cytosolic EGFP) (Lawson and Weinstein, 2002), Tg(flk1:rasmCherry) s896 (membrane-targeted mCherry) (Chi et al., 2008 ) and the nuclear-targeted EGFP reporters Tg(fli1:nEGFP) y7 (Siekmann and Lawson, 2007) and Tg(flk1:EGFP-NLS) (Blum et al., 2008) . The EC-specific driver line Tg(fliep:gal4ff) ubs4 (L.H., A.K., H-G.B. and M.A., unpublished) was used for GAL4/UAS-mediated gene over-expression. The GAL4 responder UAS lines for fluorescent protein expression Tg(UAS:Kaede) rk2 (Kaede) (Hatta et al., 2006) and Tg(UAS:RFP) (monomeric DsRed derivative) (Asakawa et al., 2008; Kawakami et al., 2004) (Nicoli et al., 2010; Parsons et al., 2009 ). We employed the flt1 transcriptional reporter line Tg(flt1: YFP) hu4624 (Geudens et al., 2010; Hogan et al., 2009a; Hogan et al., 2009b) . The following mutant alleles were used: the partially haplo-insufficient delta like 4 hypomorph dll4 j16e1 (Leslie et al., 2007) , the kinase dead kinase insert domain receptor-like hypomorph allele kdrl y17 (Covassin et al., 2009; Covassin et al., 2006 ) the mind bomb null mib m178 (Itoh et al., 2003; , the plxnD1/out of bounds null obd fov01b (Childs et al., 2002; Torres-Vazquez et al., 2004) and the phospholipase c gamma 1 null plcg1 y18 (Covassin et al., 2009 ). Homozygous mutants were employed unless otherwise indicated.
Genotyping of Zebrafish Adults and Embryos
Animals were genotyped using PCR products amplified from genomic DNA isolated from fin clips (adults) or from fixed embryos (whole or head/trunk clips). To collect fin clips animals were anesthetized in a 100 mg/ml Tricaine (Sigma) aqueous solution. Then a section of the caudal fin was excised with scissors and placed on dry ice. Fin clips were digested with 100 ul of DNA isolation buffer (10mM Tris-HCl pH 8, 50 mM EDTA pH 8, 200 mM NaCl, 0.05 mg/ml Proteinase K (Sigma), 5% SDS (sodium dodecyl sulphate, (Sigma), water) for 10 min at 98 C, followed by addition of 10 µl of 0.5 mg/ml Proteinase K and 3 hours incubation at 55 C and 10 minute Proteinase K heatinactivation at 98 C. Individual embryos or tissue clips were digested in 100 ul of digestion buffer (10mM Tris-HCl pH 7.5, 50mM KCl, 50mM EDTA pH 8, 0.1% Tween, 0.1% Igepal (Sigma), water), for 10 minutes at 98 C, followed 12 minutes at 4 C. Next 10 µl of Proteinase K (10mg/ml, in water) was added to the mix, which was then incubated at 55 C for 12 hours, followed by 10 minute Proteinase K heat-inactivation at 98 C. Fin and embryo digests were used as PCR templates (primers listed at the end of the Supplemental Information). The resulting products were purified using a PCR purification kit (Qiagen) and digested with diagnostic restriction enzymes or sequenced (Macrogen USA).
dll4
j16e1 Genotyping: a 580 bp genomic fragment was amplified by PCR with dll4-F and dll4-R primers and the product purified and sequenced to verify the presence of the C to T transition responsible for the G270S substitution (Leslie et al., 2007) . mib m178 Genotyping: a 481 bp genomic fragment was amplified by PCR with mib-F and mib-R primers and the product digested with SmlI (New England BioLabs's R0597S). This enzyme does not cut the PCR product from the WT allele but cuts the PCR product from the mutant mib m178 allele into diagnostic 462 and 19 bp fragments. Alternatively, adult mib m178 /+ carriers were identified by performing pair-wise crosses and scoring the progeny for morphological abnormalities at 28 hpf (tail curl and abnormal head shape) and 48-72 hpf (edema).
obd
fov01b Genotyping: a 551 bp genomic fragment was amplified by PCR with obd-F and obd-R primers and the product was PCR purified and sequenced to check for presence of the C to A transversion that converts Tyr318 to a stop codon (TorresVazquez et al., 2004) .
plcg1
y18 Genotyping: a 718 bp genomic fragment was amplified by PCR with plcg1-F and plcg1-R primers and the product was PCR purified and sequenced to check for presence of G to A transition in a donor splice acceptor site (GT) that leads to the protein's truncation at the X-catalytic domain (Covassin et al., 2009 ).
Zebrafish Husbandry and Embryo Collection
Zebrafish adults and embryos were maintained and handled using standard laboratory conditions in compliance with New York University IACUC guidelines (Kimmel et al., 1995) . Briefly, embryos were collected every 30 minutes (min) from natural spawnings and generally incubated at 28.5ºC in standard embryo medium until fixation/imaging. Embryos were staged by age (hpf) and/or morphological criteria. To block melanin synthesis and preserve embryonic transparency we incubated the embryos starting at 6-8 hpf with standard embryo medium supplemented with 0.003% Phenyl-Thio-Urea (PTU; Sigma P-7629) (Karlsson et al., 2001 ). This treatment does not interfere with vascular development (Isogai et al., 2001 ).
Immuno-Fluorescent Staining of Embryos
Embryos were fixed overnight at 4 o C in 4% paraformaldahyde (Sigma) dissolved in 1x Phosphate Buffered Saline pH 7.5 (1x PBS). Embryos were then rinsed four times for 20 minutes (min) in PBST (0.1% Tween (Sigma) in 1x PBS) and then permeabilized for 25 min with cold (-20 C) acetone (Fisher Scientific). After acetone treatment, embryos were rinsed in PBST four times for 20 min and then blocked 2 hrs in blocking solution (2% Bovine Serum Albumin (Sigma) in PBST). Embryos were incubated overnight with primary antibodies diluted in blocking solution at 4 C, followed by four 20 min washes in PBST. Embryos were then incubated with secondary antibodies diluted in blocking solution for either 2 hours at room temperature or overnight at 4 C. Following four 20 min washes in PBST the embryos were mounted and imaged. The following primary antibodies were used: to visualize somite boundaries we used either mouse antiLaminin 2, clone 5H2 (1:200 dilution; for 21 hpf embryos, Millipore's MAB1922) or mouse anti-phospho-FAK, Tyr397 (1:200 dilution; for 23-32 hpf embryos, Millipore's MAB1144). To enhance the visualization of fluorescent proteins we used rabbit antiDsRed, C20 (1:500 dilution; Santa Cruz Biotech's sc33354) for both mCherry and DsRed and rabbit anti-GFP (1:200 dilution; Invitrogen's A11122) for EGFP.
The following secondary antibodies were used: Alexa Fluor 546 goat anti-rabbit IgG H+L (1:200 dilution; Invitrogen's A11010), Alexa Fluor 647 goat anti-mouse IgG H+L (1:200 dilution; Invitrogen's A21236) and Alexa Fluor 488 donkey anti-rabbit IgG H+L (1:500 dilution; Invitrogen's A21206).
Generation and Validation of the EC-Specific Gal4FF Driver Tg(fliep:gal4ff) ubs4
Construction of the EC-Specific Gal4FF Driver Vector pTol[fli1ep:gal4ff]: A PCR fragment containing the ORF of the GAL4-VP16 derivative Gal4FF (GFF) was amplified from the pT2KhspGFF vector (Asakawa et al., 2008; Kawakami et al., 2004 ) using primers GFF-F and GFF-R (listed at the end of the Supplemental Information) and directionally TOPO-cloned into the entry vector pENTR/D-TOPO (Invitrogen). The resulting pENTR:GFF entry clone was recombined with the endothelial-specific destination vector pTolfli1epDest (Villefranc et al., 2007) embryos (Hatta et al., 2006) . Injected embryos were visually screened under an epifluorescent microscope and animals with strong Kaede fluorescence in the developing vasculature were raised to adulthood to obtain putative G0 founders with mosaic transgenic germlines. G0 adults were individually out-crossed to Tg(UAS: Kaede) rk2 fish and their F1 progeny screened visually as described. Individual G0s that yielded progeny with vascular Kaede expression were selected to establish three independent Tg(fli1ep:GFF) lines with the allele designations B326, C327 and D327 (used in this study). . The resulting progeny was visually inspected under an epifluorescent microscope. Embryos with RFP (red) and EGFP (green) co-expression were selected for confocal microscopy. A virtually complete overlap between RFP (driven by Tg(fliep:gal4ff) ubs4 ) and EGFP (from the Tg(fli:EGFP) y1 reporter) expression was observed, confirming the endothelial-specificity of the Tg(fliep:gal4ff) ubs4 driver line, albeit a variable degree of ectopic expression can be sometimes observed ( Figure S5A ).
Cloning and Construction of Expression Vectors
Isolation of mflt1 and sflt1 cDNAs: We isolated total mRNA from a pool of 24 hpf wild type EK embryos with the Dynabeads mRNA Direct Kit (Invitrogen) and used the Thermoscript RT-PCR System (Invitrogen) to prepare cDNA from it. The cDNA was PCR amplified with primers full-length mflt1 F/R and full-length sflt1 F/R, respectively (primers listed at the end of the Supplemental Information), to isolate mflt1 and sflt1 cDNAs including both the native KOZAK sequence and the full ORF. The sequence of the sflt1 mRNA can be accessed at GenBank (Accession Number: HQ322130, released upon publication). The corresponding PCR products were cloned into pCR8/GW/TOPO TA entry vector (Invitrogen) according to the manufacturer's instructions to make pCR8-mflt1 and pCR8-sflt1 Gateway entry clones flanked by attL1 and attL2 sites. (Paquet et al., 2009 ).
Tol2-Based Constructs for GAL4/UAS-Mediated
Tol2-Based Transient Transgenesis of Gene Expression Vectors: 100 pg of Tol2 transposase mRNA synthesized in vitro with the mMessage mMachine Kit (Ambion) and plasmid DNA (20 pg of each plasmid) were co-injected into 1-cell stage embryos.
Genes Visualized by WISH and Riboprobe Synthesis
Riboprobes were made to visualize transcripts of the following genes: the panendothelial marker cdh5/ve-cdh (Larson et al., 2004) , the Notch ligands deltac/dlc (Smithers et al., 2000) and dll4 (Covassin et al., 2009) , the venous marker and Notchrepressed gene eph receptor B4a/ephb4a (Rodriguez et al., 2008) , the arterial marker and Notch-activated gene ephrin-B2a/efnb2 (Covassin et al., 2009) , the VEGF receptors type 2 flk1/kdrl (Choi et al., 2007) , type 1 fms-related tyrosine kinase 1/flt1 (Bussmann et al., 2007) and type 3 fms-related tyrosine kinase 3/flt4 , the arterial marker and Notch effector hairy/enhancer-of-split related with YRPW motif 2/hey2/gridlock/grl (Rodriguez et al., 2008) , notch5 (Rodriguez et al., 2008) , the Sema receptor plexinD1/plxnD1 (Torres-Vazquez et al., 2004) , the marker of the dorsal side of the aorta T-box 20/tbx20 (Rodriguez et al., 2008) and vascular endothelial growth factor c/vegfc (Ober et al., 2004) . Synthesis of Antisense Riboprobes: All riboprobes were generated from linearized plasmid templates using RNA polymerases and labeled with Digoxigenin Labeling Mix (Roche), except for cdh5, which was labeled with Fluorescein Labeling Mix (Roche). To generate flt1 riboprobes we PCR amplified sflt1 (420 nts) and mftl1-specific (690 nts) products from WT 24 hpf EK cDNA using primers sflt1 in situ probe F/R and mflt1 in situ probe F/R (primer sequences provided at the end of the Supplemental Information). The resulting DNA products were subsequently cloned into the TOPO TA Dual Promoter vector (Invitrogen). The resulting vectors were linearized with SpeI (New England BioLabs) and riboprobes made with T7 RNA Polymerase (Roche).
Confocal and Transmitted Light Imaging
Fixed and stained embryos were mounted in 1% low melt agarose (National Diagnostics) dissolved in water. Live embryos were mounted in 0.6% low melt agarose and submerged in standard embryo medium supplemented with 0.003% PTU and 50-100 mg/ml of the anesthetic Tricaine methanesulfonate (Sigma E10521, as in . Confocal images were taken with a Leica TCS SP5 microscope (Leipzig, Germany) using a water dipping 40x lens with a NA of 0.8 and 1.3 digital zoom. The 488, 561, 647 nm laser lines were employed. Images were processed with ImageJ (1.42q) and Adobe Photoshop7 software. Confocal time-lapse imaging was performed as described above (without digital zoom), images were collected for ~12 hrs with scans every 6 minutes. Image files were processed using ImageJ (National Institutes of Health) and Imaris (Bitplane Inc.) software and set to play as a movie file at 10 fps. Transmitted light images of whole mount RNA in situ hybridized embryos and drug treated animals were captured with a Zeiss Axiocam (HRc) digital camera on Zeiss' Axioplan and M2Bio microscopes. Images were processed with AxioVision (4.8) and Adobe Photoshop 7 software.
Morpholino Oligos (MOs) and Validation of Gene Knockdown
To specifically knockdown sflt1 we used 20 ng/embryo of splice-blocking sflt1-splice morpholino (5'-GCCGCTATAAAGAATAAGGGCCTGA-3'), which targets the complementary sequence 5'-tcaggcccttattctttatagCGGC-3' (lower case, intron; uppercase, exon) of the exon 11a splice acceptor site (see Figure S4A) . As a negative control we used 20 ng/embryo of its mismatched cognate, sflt1-ctrl morpholino (5'-GCCCCAATAAACAAAAAGCGCCTGA-3') (mismatches underlined). To verify the effectiveness and specificity of flt1 morpholinos we first extracted total mRNA from pools of 30-40 embryos (both sflt1-splice and sflt1-ctrl morphants) using the Dynabeads mRNA Direct Kit (Invitrogen) as per the manufacturer's instructions. cDNAs were synthesized using Thermoscript RT-PCR System (Invitrogen) . To analyze the splicing of sflt1 ( Figure S4B ) we used the synthesized cDNAs as templates for RT-PCR reactions to amplify a sflt1-specific 85 bp fragment spanning exons 10 and 11a (primers: rtpcr MO sflt1 F and R; sequences below) and an mflt1-specific 81 bp fragment spanning mflt1's exons 10 and 11b (primers: rtpcr MO sflt1 F and R; sequences below). To verify the gene targeting specificity of the morpholino we amplified a bactin2 100 bp fragment spanning exons 5 and 6 with cDNA from both sflt1-splice and sflt1-ctrl morphants (primers: rtpcr MO bactin2 F/R). We used additional already-validated splice-blocking morpholinos: 10 ng/embryo of pan-flt1 MO (to knockdown both flt1 isoforms; 5'-AAGCAGACTCTCACCATTTACCACC-3') and 10 ng/embryo of the mflt1-specific mflt1-splice MO (5'-CAGCAGTTCACTCACATCTCCGTTC-3') (Rottbauer et al., 2005) . To target mib we used the 10 ng/embryo of mib MO 5'-GCAGCCTCACCTGTAGGCGCACTGT-3' (Burns et al., 2005; Itoh et al., 2003) . All morpholinos were acquired from GeneTools, LLC (Philomath, OR).
HUVEC (Human Umbilical Vein Endothelial Cell) Experiments
Reagents: Recombinant human VEGF165 (#293-VE) and Sema3E (#3239S3) were purchased from R&D Systems (Minneapolis, MN). Control (sc-108080), PLXND1 (sc-45585-V) and FLT1 (sc-29319-V) shRNA (human) lentiviral particles were purchased from Santa Cruz biotechnology Inc. (Santa Cruz, CA). HUVECs and culture medium (Vasculife EnGS Complete Kit, LL-0002) were purchased from Lifeline Cell Technology (Frederich, MD) and cultured according to the manufacturer's instructions. ELISA kits for human soluble sFLT1/FLT1 (DVR100B, R&D Systems) were used according to the manufacturer's specifications. HUVEC Cell Proliferation Assay: 5 X 10 4 HUVECs/well were seeded in a 12 well plate. Next day, HUVECs were infected with control, PLXND1 or FLT1 shRNA (human) lentiviral particles. After 24 hours of infection, the medium was changed and HUVECs were stimulated with/without VEGF165 (50 ng/mL) and/or Sema3E (10 nM). HUVECs were counted after 36 hours of stimulation. HUVECs were used between passages 2-4. Experiments were done twice in triplicate.
Enzyme Linked Immunosorbent Assay (ELISA)-Based Quantification of FLT1 Made by HUVECs: HUVECs were cultured, infected with shRNA lentivirus particles and costimulated with both VEGF165 and Sema3E as described above. Protein extracts were made from HUVECs after 36 hours of stimulation. Protein extracts were made after discarding the cell membrane fraction and hence these extracts are enriched for sFLT1 due to the lack of the mFLT1-containing membrane fraction. 2.5 ug of total protein extract was used for ELISA assays. Briefly, samples were incubated in a 96-well plate pre-coated with a capture antibody against sFlt1 for 2 hours. The wells were then washed four times with buffer and incubated with a secondary antibody against sFlt1 conjugated to horseradish peroxidase for 2 hours. The plates were then washed four times, substrate solution was added for 30 minutes, and optical density was determined at 450 nm. Protein levels were calculated using a standard curve derived from solutions of recombinant sFLT1 proteins at known concentrations. HUVECs were all used between passages 2-4. ELISA-based measurements of FLT1 made by HUVECs were done in duplicate twice.
Statistical Analyses: The data from ELISA assays was analyzed using the 2-tailed Student's t test. Differences were considered significant when the P value was >0.05. Error bars, s.e.m.
Validation of FLT1 and PLXND1 Knockdown in HUVECs: qPCR was used to determine the specificity and measure the knockdown efficiency of the shRNA (human) lentiviral particles on FLT1 and PLXND1 and mRNA abundance. The transcript levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used for normalization. The sequences of the primers used for qPCR quantification are listed below. Briefly, total RNA was isolated from HUVECs at the end of each experiment using TRIzol (Invitrogen). RNA was reverse-transcribed using random hexamers and the SuperScript First Strand Synthesis kit (Invitrogen). Gene expression was measured by quantitative RT-PCR (ABI PRISM 7900) using SYBR Green master mix (Applied Bio-systems). Primers a) Mutant Genotyping dll4-F 5'-ACATGGTTTATGGTGTGTGCAAA-3'; dll4-R 5'-TGATGGGGTTTAGGGGTCTCC-3'; mib-F, 5'-GCGGCCTTCACCAGCTCTT-3'; mib-R, 5'-CCGCTGCTGTCACAAAAGT-3'; obd-F, CACAGCAAAGAGGACCTGCG obd-R, CCCTGGATGACGCTGTCCA plcg1-F, 5'-TTTGTCCCCTTTTCTCATTCA-3'; plcg1-R, 5'-AGGGCACCTATGATGCAAAC -3'. b) Gal4FF ORF Amplification GFF-F 5'-CACCATGAAGCTACTGTCTTC-3'; GFF-R 5'-TTAGTTACCCGGGAGCATATC-3'; c) qPCR Quantification qpcr bactin2 F, 5'-TGACAGGATGCAGAAGGAGA-3'; qpcr bactin2 R, 5'-GCCTCCGATCCAGACAGAGT-3'; qpcr FLT1 F, 5'-GCTTCTCACAGGATCTAGTTC-3'; qpcr FLT1 R, 5'-CTGCTTCCCCCCTGCATTG-3'; qpcr GAPDH F: 5'-GCTCATTTCCTGGTATGACAAC -3'; qpcr GAPDH R: 5'-GGGGAGATTCAGTGTGGTGG-3'; qpcr mflt1 F, 5'-TTCTCCATACCCAGGAGTGC-3'; qpcr mflt1 R, 5'-GATTTGGTAGATTTCAGGTGTGG-3'; qpcr PLXND1 F, 5'-GGCTTCTCAAGATCAACCTG-3'; qpcr PLXND1 R, 5'-TCACCCTGGCCATCTGGTG-3'; qpcr sflt1 F, 5'-ATCCGTGCCCTCCAAAAG-3'; qpcr sflt1 R, 5'-GCCCACAACTCCACTCTCC-3'; qpcr YFP F, 5'-CACATGAAGCAGCACGACTT-3'; qpcr YFP R, 5'-GGTCTTGTAGTTGCCGTCGT-3'; d) Cloning Full Length flt1 Isoforms full length mflt1 F, 5'-AGACCAAGAGAATGTTCGATATAT-3'; full length mflt1 R, 5'-TTAGAAACTGGGGTAAAGAAGAT-3'; full length sflt1 F, 5'-ACCAAGAGAATGTTCGATATATTATTTGTGATGAT-3'; full length sflt1 R, 5'-CCACAACTCCACTCTCCCTGGG-3'; e) Synthesis of Riboprobes Specific for flt1 Isoforms mflt1 in situ probe F, 5'-CCTCTTCTTCTTGAAGATTTGATTTCTTACAGCTTT-3'; mflt1 in situ probe R, 5'-AGGGATCTCTTTGTGCAAATCTTCAAAA -3'; sflt1 in situ probe F, 5'-TGATAGCGGCTGGATGGGCTT-3'; sflt1 in situ probe R, 5'-ATTAAACTGTAGTTCCAGGGGTGCAGAG-3'; f) Validation of sflt1 MO Knockdown and Specificity rtpcr MO bactin2 F, 5'-TGACAGGATGCAGAAGGAGA-3'; rtpcr MO bactin2 R, 5'-GCCTCCGATCCAGACAGAGT-3'; rtpcr MO mflt1 F, 5'-CCACCACCTCAAATCCAATG-3'; rtpcr MO mflt1 R, 5'-AGTCCAGGACGAAGGAGGAG-3'; rtpcr MO sflt1 F, 5'-ATCCGTGCCCTCCAAAAG-3'; rtpcr MO sflt1 R, 5'-GCCCACAACTCCACTCTCC-3';
